Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

If successful, the conjugate drugs could reduce that to four injections per year, he says. MariTide, a monoclonal antibody that Amgen is developing as a weight-loss drug, takes a similar dual ...

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

One of the key focus areas is the development of MariTide, a novel treatment for obesity, obesity-related conditions, and type 2 diabetes. The Phase II study of MariTide is progressing well ...

The company’s investigational treatment for obesity and type 2 diabetes, MariTide, is of particular interest, with Phase 2 trial data expected in the second half of 2025. Analysts from Goldman Sachs ...